case_images: PMC10405981_01
case_images: Histopathology slide of adenocarcinoma with thyroid transcription factor-1 positive stain
case_images: JCAS-9-507-g001.jpg
case_images: PMC10405981_01_JCAS-9-507-g001.jpg
case_images: F1
case_images: Histopathology of the lesion was significant for adenocarcinoma grade III, thyroid transcription factor-1 positive [Figure 1].
case_images: Staging positron emission tomography-computed tomography scan showing a hypermetabolic left lower lobe lung mass with mediastinal and left level IV cervical lymphadenopathy
case_images: JCAS-9-507-g002.jpg
case_images: PMC10405981_01_JCAS-9-507-g002.jpg
case_images: F2
case_images: A positron emission tomography-computed tomography (PET-CT) scan revealed a highly active mass in the lower left lobe of the lung, accompanied by lymph node enlargement in the mediastinum and left level IV cervical region [Figure 2].
case_images: Radiotherapy plan for primary lung mass showing target volume coverage and dose volume histogram demonstrating planning volume radiation coverage doses to organs at risk
case_images: JCAS-9-507-g003.jpg
case_images: PMC10405981_01_JCAS-9-507-g003.jpg
case_images: F3
case_images: Followed by concurrent chemoradiation therapy using 55 gray units in 20 fractions [Figure 3] with cisplatin 100 mg/m2 on Day 1 and vinorelbine 50 mg/m2 on Day 1, 8 and 15.
case_images: Histopathology slide of metastatic lesion showing adenocarcinoma from primary lung cancer showing epithelial growth factor receptor mutation and anaplastic lymphoma kinase rearrangement not detected
case_images: JCAS-9-507-g004.jpg
case_images: PMC10405981_01_JCAS-9-507-g004.jpg
case_images: F4
case_images: Histopathology showed metastatic adenocarcinoma from the primary lesion with EGFR mutated at exon 21 and anaplastic lymphoma kinase rearrangement not detected [Figure 4].
case_images: Positron emission tomography-computed tomography scan showing hypermetabolic soft tissue mass in paraduodenal/peripancreatic area inseparable from uncinated process of pancreas
case_images: JCAS-9-507-g005.jpg
case_images: PMC10405981_01_JCAS-9-507-g005.jpg
case_images: F5
case_images: PET-CT showed hypermetabolic activity in the mass [Figure 5].
case_images: Coronal and axial sections of computed tomography scan post 6 months of erlotinib treatment showing complete resolution of pancreatic mass
case_images: JCAS-9-507-g006.jpg
case_images: PMC10405981_01_JCAS-9-507-g006.jpg
case_images: F6
case_images: After 6 months, the CT scan revealed disease remission [Figure 6].